PE20170069A1 - {ACID 4 - [(2 - {[3,5-BIS (TRIFLUORomethyl) BENZYL] - [(2R, 4S) -1- (ETOXICARBONYL) -2-ETHYL-6- (TRIFLUOROMETIL) -1,2,3, 4-TETRAHYDROQUINOLIN-4-IL] AMINO} PYRIMIDIN-5-IL) OXI] BUTANOIC} AS INHIBITOR OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) AND COMPOSITIONS THAT INCLUDE IT - Google Patents
{ACID 4 - [(2 - {[3,5-BIS (TRIFLUORomethyl) BENZYL] - [(2R, 4S) -1- (ETOXICARBONYL) -2-ETHYL-6- (TRIFLUOROMETIL) -1,2,3, 4-TETRAHYDROQUINOLIN-4-IL] AMINO} PYRIMIDIN-5-IL) OXI] BUTANOIC} AS INHIBITOR OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) AND COMPOSITIONS THAT INCLUDE ITInfo
- Publication number
- PE20170069A1 PE20170069A1 PE2016001430A PE2016001430A PE20170069A1 PE 20170069 A1 PE20170069 A1 PE 20170069A1 PE 2016001430 A PE2016001430 A PE 2016001430A PE 2016001430 A PE2016001430 A PE 2016001430A PE 20170069 A1 PE20170069 A1 PE 20170069A1
- Authority
- PE
- Peru
- Prior art keywords
- trifluoromethyl
- tetrahydroquinolin
- cetp
- butanoic
- pyrimidin
- Prior art date
Links
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 title abstract 4
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 title 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical group F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- NRWORBQAOQVYBJ-GJZUVCINSA-N obicetrapib Chemical compound N=1C=C(OCCCC(O)=O)C=NC=1N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NRWORBQAOQVYBJ-GJZUVCINSA-N 0.000 abstract 3
- 229950004285 obicetrapib Drugs 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 2 - {[3,5-bis (trifluoromethyl) benzyl] - [(2R, 4S) -1-ethoxycarbonyl-2-ethyl-6-trifluoromethyl-1, 2, 3 , 4-tetrahydroquinolin-4-yl] amino} pyrimidin-5-yl Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se refiere al compuesto obicetrapib (acido 4-[(2-{[3, 5-bis(trifluorometil)bencil]-[(2R, 4S)-1-etoxicarbonil-2-etil-6-trifluorometil-1, 2, 3, 4-tetrahidroquinolin-4-il]amino}pirimidin-5-il)oxi]butanoico) o una sal farmaceuticamente aceptable del mismo, el cual es un inhibidor de la proteina de transferencia del ester de colesterilo (CETP). Tambien se refiere a composiciones farmaceuticas que comprenden obicetrapib o una sal farmaceuticamente aceptable del mismo. Obicetrapib es util en el tratamiento de sujetos que padecen o tienen un riesgo incrementado de enfermedades cardiovasculares, en particular hiperlipidemia o dislipidemia, o ambasRefers to the compound obicetrapib (acid 4 - [(2 - {[3,5-bis (trifluoromethyl) benzyl] - [(2R, 4S) -1-ethoxycarbonyl-2-ethyl-6-trifluoromethyl-1, 2, 3 , 4-tetrahydroquinolin-4-yl] amino} pyrimidin-5-yl) oxy] butanoic) or a pharmaceutically acceptable salt thereof, which is a cholesteryl ester transfer protein (CETP) inhibitor. It also refers to pharmaceutical compositions comprising obicetrapib or a pharmaceutically acceptable salt thereof. Obicetrapib is useful in the treatment of subjects suffering from or at increased risk of cardiovascular diseases, particularly hyperlipidemia or dyslipidemia, or both.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PE2016001430A PE20170069A1 (en) | 2014-02-05 | 2014-02-05 | {ACID 4 - [(2 - {[3,5-BIS (TRIFLUORomethyl) BENZYL] - [(2R, 4S) -1- (ETOXICARBONYL) -2-ETHYL-6- (TRIFLUOROMETIL) -1,2,3, 4-TETRAHYDROQUINOLIN-4-IL] AMINO} PYRIMIDIN-5-IL) OXI] BUTANOIC} AS INHIBITOR OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) AND COMPOSITIONS THAT INCLUDE IT |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PE2016001430A PE20170069A1 (en) | 2014-02-05 | 2014-02-05 | {ACID 4 - [(2 - {[3,5-BIS (TRIFLUORomethyl) BENZYL] - [(2R, 4S) -1- (ETOXICARBONYL) -2-ETHYL-6- (TRIFLUOROMETIL) -1,2,3, 4-TETRAHYDROQUINOLIN-4-IL] AMINO} PYRIMIDIN-5-IL) OXI] BUTANOIC} AS INHIBITOR OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) AND COMPOSITIONS THAT INCLUDE IT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170069A1 true PE20170069A1 (en) | 2017-03-19 |
Family
ID=58608708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016001430A PE20170069A1 (en) | 2014-02-05 | 2014-02-05 | {ACID 4 - [(2 - {[3,5-BIS (TRIFLUORomethyl) BENZYL] - [(2R, 4S) -1- (ETOXICARBONYL) -2-ETHYL-6- (TRIFLUOROMETIL) -1,2,3, 4-TETRAHYDROQUINOLIN-4-IL] AMINO} PYRIMIDIN-5-IL) OXI] BUTANOIC} AS INHIBITOR OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) AND COMPOSITIONS THAT INCLUDE IT |
Country Status (1)
| Country | Link |
|---|---|
| PE (1) | PE20170069A1 (en) |
-
2014
- 2014-02-05 PE PE2016001430A patent/PE20170069A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124084T1 (en) | AMIDE SUBSTITUTED PYRIDINYLTRIAZOLE DERIVATIVES AND USES THEREOF | |
| EA202090955A1 (en) | METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS | |
| EA201792229A1 (en) | Bromodomain inhibitors | |
| EA201792047A1 (en) | NEW CONNECTIONS | |
| EA201691516A1 (en) | DIHYDROPYRROLOPIRIDINOVYY INHIBITORS ROR-GAMMA | |
| EA201591727A1 (en) | BIARYLAMIDE COMPOUNDS AS KINASE INHIBITORS | |
| EA201591908A1 (en) | Condensed Heterocyclic Compounds As Protein Kinase Inhibitors | |
| EA201690159A1 (en) | METHODS AND COMPOSITIONS FOR CANCER TREATMENT | |
| UA110612C2 (en) | DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYRBORONIC ACID | |
| EA201390803A1 (en) | Bromodomain inhibitors and their use | |
| EA201200098A1 (en) | CONDENSED IMIDAZOLES AND CONTAINING THEIR COMPOSITIONS INTENDED FOR THE TREATMENT OF PARASITIC DISEASES, SUCH AS MALARIUM | |
| UA104489C2 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| MX2018004043A (en) | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids. | |
| EA201692049A1 (en) | Heteroaryl substituted heterocyclic sulfones | |
| MX2018001205A (en) | Inhibitor of the mutated isocitrate dehydrogenase idh1 r132h. | |
| EA201692470A1 (en) | PHARMACEUTICAL COMBINATIONS | |
| EA201990949A1 (en) | SULPHOXIALKYL ORGANIC NITRO COMPOUNDS AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE | |
| EA201791898A1 (en) | NEW ANTIBODIES CONNECTING WITH TFPI AND CONTAINING THEIR COMPOSITION | |
| EA201692402A1 (en) | MEDICAL FORMS FOR LOCAL APPLICATION AND THEIR USE | |
| EP3528820A4 (en) | NOVEL PEGYLATED APELINE LIPOSOMAL FORMULATIONS FOR THE TREATMENT OF CARDIOVASCULAR SYSTEM-RELATED DISEASES | |
| BR112016029067A2 (en) | "compound, pharmaceutical composition, and methods for inhibiting the renal external medullary potassium channel, for causing diuresis, natriuresis or both and for treating one or more disorders". | |
| EA201691796A1 (en) | N-SUBSTITUTED ASYMMETRIC UREA AND THEIR APPLICATION IN MEDICINE | |
| MX376135B (en) | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND HMG COA REDUCTASE INHIBITORS | |
| CR20160353A (en) | CHOLESTERILE ESTER TRANSFER PROTEIN INHIBITOR (CETP) AND PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THE INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | |
| MD4629B1 (en) | Treatments for fibrosis and cancer |